Reagents for reducing leukocyte interference in immunoassays

US9316638B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-9316638-B2
Application numberUS-201514673364-A
CountryUS
Kind codeB2
Filing dateMar 30, 2015
Priority dateApr 30, 2010
Publication dateApr 19, 2016
Grant dateApr 19, 2016

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

Methods and devices for reducing interference from leukocytes in an analyte immunoassay are provided. In one embodiment, a method is provided comprising the steps of amending a biological sample such as a whole blood sample with one or more leukocidal reagents that reduce or eliminate the metabolic activity of leukocytes, and performing an immunoassay on the amended sample to determine the concentration of analyte in the sample. Preferably, the sample is amended with one or more enzymes and optionally one or more enzyme substrates and cofactors.

First claim

Opening claim text (preview).

What is claimed is: 1. A kit for performing an electrochemical immunoassay for a target analyte in a whole blood sample comprising: a leukocidal reagent configured to substantially inhibit phagocytic activity of leukocytes in the whole blood sample, wherein the leukocidal reagent is a mitochondrial electron transport inhibitor or a mitochondrial membrane uncoupling agent, and electrochemical immunoassay reagents for detecting at an immunosensor the target analyte in the leukocidal reagent-treated whole blood sample. 2. The kit of claim 1 , wherein the leukocidal reagent is the mitochondrial electron transport inhibitor. 3. The kit of claim 1 , wherein the leukocidal reagent is the mitochondrial membrane uncoupling agent. 4. The kit of claim 1 , wherein the leukocidal reagent is the mitochondrial electron transport inhibitor or the mitochondrial membrane uncoupling agent and selected from the group consisting of cyanide, antimycin, rotenone, malonate, carbonyl cyanide p-[trifluoromethoxyl]-phenyl-hydrozone, 2,4-dinitrophenol, and oligomycin. 5. The kit of claim 1 , further comprising the immunosensor comprising an immobilized first antibody to the target analyte, and a labeled second antibody to the target analyte, wherein the immunoassay is a sandwich assay. 6. The kit of claim 1 , further comprising the immunosensor comprising an immobilized antibody to the target analyte, and the target analyte is labeled, wherein the immunoassay is a competitive assay. 7. The kit of claim 1 , further comprising beads opsonized for the leukocytes. 8. The kit of claim 1 , wherein the whole blood sample is amended with an anticoagulant. 9. The kit of claim 1 , wherein the target analyte is selected from the group consisting of Troponin I (TnI), Troponin T (TnT), Brain Natriuretic Peptide (BNP), N-terminal of the Prohormone Brain Natriuretic Peptide (NTproBNP), Prohormone Brain Natriuretic Peptide (proBNP), Human Chorionic Gonadotropin (HCG), Thyroid-Stimulating Hormone (TSH), Neutrophil Gelatinase Associated Lipocalin (NGAL), theophylline, digoxin, and phenytoin. 10. The kit of claim 1 , further comprising the immunosensor. 11. The kit of claim 10 , wherein the leukocidal reagent is positioned upstream of the immunosensor such that the whole blood sample is contacted with the leukocidal reagent prior to contacting the immunosensor.

Assignees

Inventors

Classifications

  • Liberation or purification of sample or separation of material from a sample [e.g., filtering, centrifuging, etc.] · CPC title

  • Digestion or removing interfering materials · CPC title

  • by changing the physical or chemical properties of the medium or immunochemicals, e.g. temperature, density, pH, partitioning · CPC title

  • Improving reaction conditions or stability, e.g. by coating or irradiation of surface, by reduction of non-specific binding, by promotion of specific binding · CPC title

  • Improving reaction conditions, e.g. reduction of non-specific binding, promotion of specific binding · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US9316638B2 cover?
Methods and devices for reducing interference from leukocytes in an analyte immunoassay are provided. In one embodiment, a method is provided comprising the steps of amending a biological sample such as a whole blood sample with one or more leukocidal reagents that reduce or eliminate the metabolic activity of leukocytes, and performing an immunoassay on the amended sample to determine the conc…
Who is the assignee on this patent?
Abbott Point Of Care Inc, Abbott Point Of Care Inc
What technology area does this patent fall under?
Primary CPC classification G01N33/54393. Mapped technology areas include Physics.
When was this patent published?
Publication date Tue Apr 19 2016 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).